

### Role of Intravenous Iron in Iron Concentration and Fracture Recovery in Mice with Iron-Deficiency Anemia

Partnership tor Scientific Inquiry

<sup>1</sup>Biomedical Engineering, Oregon Health & Science University, Portland, OR; <sup>2</sup>Orthopaedics & Rehabilitation, Oregon Health & Science University,

<sup>3</sup>Bioengineering, University of Oregon, Eugene, OR

Kaia Matthias, Victoria R Duke<sup>1</sup>, Cynthia Alcazar<sup>1</sup>, Natasha McKibben<sup>2</sup>, Zachary M Working<sup>2</sup>, Nick J Willett<sup>3</sup>, & Karina Nakayama<sup>1</sup>

Building tomorrow's researchers today


#### Introduction

#### Iron deficient anemia = low hemoglobin & iron

- Affects 90% of post-op orthopedic trauma patients (Landers et al., 2025)
- Associated with longer stays, infections, transfusions, and poor recovery
- Transfusions used only for severe cases; moderate IDA often untreated
- Moderate IDA can last 6+ months, worsening fatigue, depression, quality of life.

### Objective

This study evaluates the role of intravenous iron therapy (IVIT) on iron concentration and fracture recovery in a preclinical mouse model of iron deficient anemia (IDA)



### Results Mobility -Female Mobility -Male P<sub>group</sub> =0.0064 o group <0.001 Days Days 3 Hind Leg Weight Distribution- Females Hind Leg Weight Distribution- Males 1.5-Days

Figure 3. Male and Female graphs show an increase in weight distribution for the IVIT group compared to untreated IDA. Weight distribution measured over 28 days in male (left) and female (right) subjects.

## Femurs Standard IV Iron Control Untreated IDA

Conclusion

#### Findings IDA groups had reduced iron levels, decreased mobility and delayed return to weightbearing.

IVIT groups showed higher iron levels, improved mobility and a faster return to weightbearing.

IVIT may be a promising treatment for orthopedic trauma patients with IDA.

### **Next Steps**

How is bone healing and strength impacted?

- Micro-CT imaging of the bone and the healing that follows fracture.
- Calus formation or other abnormalities?

### Acknowledgements

Funded by NIH (R01AR080150, R00HL136701), Medical Research Foundation of Oregon, and the Orthopaedic Trauma Association.

Thank you to everyone in the PSI Program, OHSU, and the Nakayama Lab for providing me with this amazing opportunity.

Figure 1. Mobility significantly increased in male IVIT group and notably in


- female IVIT groups. Duration of Mobility and Immobility in Male and Female Subjects Over 28 Days. Statistical significance indicated by P group values.
  - Control
  - Untreated IDA
  - Standard Dose IV Iron


# Spleen Tissue Iron Kidney Tissue Iron Liver Tissue Iron 100¬ \*\*\* \*

Figure 2. Standard dose IV iron group shows higher iron levels than untreated IDA. Iron concentration (µg Fe/g dry tissue) in kidney, liver, and spleen samples from control, untreated IDA, and standard-dose IV iron groups.

Livers

Untreated IDA





Control